HEAL Commercialization Readiness Pilot (CRP) Program: Embedded Entrepreneurs for Small Businesses in Pain Management (SB1 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

The purpose of this Funding Opportunity Announcement (FOA) is to facilitate the transition of previously funded SBIR and STTR Phase II and Phase IIB projects in pain management to the commercialization stage by providing additional assistance for private partnering activities through the Commercialization Readiness Pilot (CRP) program. Specifically, this FOA supports the addition of entrepreneurial expertise into small business leadership teams along with supporting partnering activities to aid in commercialization through private third-party funding or partnership with industry.

Clinical trials are not accepted under this FOA.


  • Letter of Intent Due Date(s): 30 days prior to the application due date

  • Application Due Dates: April 5, 2023; Sep 5, 2023; April 5, 2024; Sep 5, 2024; April 5, 2025; Sep 5, 2025

PAR-23-069 Expiration Date September 06, 2025

Agency Website

Eligibility Requirements

Only United States small business concerns (SBCs) that have had an active NIH SBIR or STTR Phase II or Phase IIB contract or grant award from NIH ICs within the last 36 months are eligible to submit applications for this opportunity. Only one CRP is allowed per Phase II or Phase IIB project. SBCs with currently active and newly awarded Phase II or Phase IIB awards from one of the participating ICs are also eligible..

Amount Description

Total funding support (direct costs, indirect costs, fee) up to $400,000, with no more than $200,000 total cost per year, may be requested.

Applicants are strongly encouraged to contact program officials prior to submitting any application and early in the application planning process. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the proposed project.

Funding Type





Engineering and Physical Sciences
Medical - Clinical Science
Medical - Translational

External Deadline

April 5, 2024